Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

• Status: Completed
• Trial end date: 2021-08-31

Summary

This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced and metastatic non-small cell lung cancer (NSCLC). The study will consist of 2 stages. In stage 1, participants from Cohorts 1 and 2 will receive niraparib plus PD-1 inhibitor; pembrolizumab and participants from Cohort 3 will receive niraparib alone. In Stage 2, participants from Cohorts 1A and 2A will receive niraparib plus the PD-1 inhibitor, TSR-042 (Dostarlimab).

• Phase: Phase 2

Details

• Lead Sponsor: Tesaro, Inc.
• Collaborators: Covance; DrugDev; INC Research; Myriad Genetics, Inc.; NeoGenomics Laboratories; Resolution Bioscience
• Treatments: Niraparib; Pembrolizumab